FMP
Gamida Cell Ltd.
GMDA
NASDAQ
Inactive Equity
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
0.0327 USD
-0.0073 (-22.32%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Ms. Abigail L. Jenkins
sector
Healthcare
industry
Biotechnology
website
https://www.gamida-cell.comexchange
NASDAQ
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to trea...
CIK
0001600847
ISIN
IL0011552663
CUSIP
M47364100
Address
5 Nahum Heftsadie Street
Phone
972 2 659 5666
Country
IL
Employee
143
IPO Date
Oct 26, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
GMDA Financial Summary
CIK
0001600847
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
M47364100
ISIN
IL0011552663
Country
IL
Price
0.03
Beta
1.03
Volume Avg.
9.38M
Market Cap
4.34M
Shares
-
52-Week
0.03-2.51
DCF
-0.03
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.04
P/B
-
Website
https://www.gamida-cell.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GMDA News
It looks like there's no news available.
